Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Phase III Study of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed Diffuse Large B-Cell Lymphoma

NCT03372837 is registered in ClinicalTrials.gov with SymBio Pharmaceuticals as lead sponsor.

NCT NCT03372837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03372837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Phase III Study of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed Diffuse Large B-Cell Lymphoma
Lead sponsor
SymBio Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
January 15, 2018
Completion date
December 31, 2019
Enrollment
40 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

assess the efficacy and safety of syb l-0501 in combination with rituximab in patients with recurrent or relapsed dlbcl